Temozolomide as adjuvant treatment newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (adults)

Closed 10 Aug 2019

Opened 11 Jul 2019

Contact

Heather Shilling

(Publishing Manager)

Specialised Commissioning

england.clinicalpolicies@nhs.net

Overview

Temozolomide is an oral medicine that works by stopping cancer cells from making deoxyribonucleic acid (DNA), thereby preventing cell growth. It is proposed to be an additional adjuvant treatment option for people with newly-diagnosed anaplastic astrocytoma who have already been treated with surgery and radiotherapy.

NHS England has launched a 30 day consultation on a policy proposition on commissioning the use of temozolomide as adjuvant treatment for adults with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy.

Related documents

Audiences

  • GPs
  • Nurses
  • Health visitors
  • Clinicians
  • Managers
  • Commissioners
  • Directors of public health
  • Pharmacists
  • Doctors
  • Midwives
  • Health care assistants
  • Healthcare scientists
  • Paramedics
  • Chiropodists/podiatrists
  • Dietitians
  • Occupation therapists
  • Orthotists
  • Orthopists
  • Prosthesists
  • Physiotherapists
  • Diagnostic radiographers
  • Therapeutic radiographers
  • Speech and language therapists
  • Childcare providers
  • Allied health professionals
  • Care-givers
  • Ophthalmic practitioners
  • Responsible officers
  • Clinical psychologists
  • Paediatric neuropsychologists
  • GP Practices
  • Clinical Nurse Specialist
  • Practice managers
  • Receptionists
  • Dental surgeons
  • Neonatal and maternity staff
  • Foundation trusts
  • Mental health trusts
  • Community healthcare trusts
  • Tribunal service
  • Strategic clinical networks (SCNs)
  • GP Practices
  • Primary care
  • Care Quality Commission
  • Health Education England
  • Health Protection Agency
  • Local Government Association
  • Monitor
  • National Institute for Health and Care Excellence
  • Health and Wellbeing boards
  • Healthwatch (national and local)
  • Health and Social Care Information Centre
  • NHS Trust Development Authority
  • NHS England Partnership Organisations
  • National directors
  • Regional directors
  • Area Team directors
  • All NHS England Staff
  • All P&I staff
  • Policy leads
  • Voluntary groups
  • Community groups
  • Charities
  • Advocacy or support organisations
  • DH third sector strategic partners
  • Regulatory bodies
  • Academic/professional institutions
  • Employer representatives
  • Employee representatives
  • Trade unions
  • Deaneries
  • Higher education institutions
  • Royal Colleges
  • Service providers
  • All interested stakeholders
  • Pharmaceutical Industry
  • Local authorities
  • Social care providers
  • Patients
  • Carers
  • Service users
  • Retailers
  • Suppliers
  • Information providers
  • Information professionals
  • Informatics professionals

Interests

  • Specialised commissioning